These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6401999)

  • 21. Inhibition of thromboxane and 12-HPETE formation by dazoxiben and its two thiophenic acid-substituted derivatives.
    Smith EF; Darius H; Ferber H; Schrör K
    Eur J Pharmacol; 1985 Jun; 112(2):161-9. PubMed ID: 3896821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion.
    Menys VC; Davies JA
    Thromb Haemost; 1983 Apr; 49(2):96-101. PubMed ID: 6346575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
    Lecompte T; Joussemet M; Hainaut J
    Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
    Brammer JP; Maguire MH
    Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour.
    Heptinstall S; Bevan J; Cockbill SR; Hanley SP; Parry MJ
    Thromb Res; 1980 Oct; 20(2):219-30. PubMed ID: 7193919
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of platelets in aspirin-sensitive bronchoconstriction in the guinea-pig; interactions with salicylic acid.
    Lefort J; Vargaftig BB
    Br J Pharmacol; 1978 May; 63(1):35-42. PubMed ID: 647162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
    FitzGerald GA; Brash AR; Oates JA; Pedersen AK
    J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet desensitization induced by arachidonic acid is not due to cyclo-oxygenase inactivation and involves the endoperoxide receptor.
    Carmo LG; Hatmi M; Rotilio D; Vargaftig BB
    Br J Pharmacol; 1985 Aug; 85(4):849-59. PubMed ID: 2994786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism.
    Patrignani P; Filabozzi P; Catella F; Pugliese F; Patrono C
    J Pharmacol Exp Ther; 1984 Feb; 228(2):472-7. PubMed ID: 6537977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dazoxiben on arterial graft thrombosis in the baboon.
    Hanson SR; Harker LA
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):57S-60S. PubMed ID: 6681705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors.
    Korbut R; Dembińska-Kieć A; Swies J; Zmuda A; Gryglewski RJ
    Thromb Haemost; 1987 Oct; 58(3):827-30. PubMed ID: 3324381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
    Gresele P; Blockmans D; Deckmyn H; Vermylen J
    J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
    Winocour PD; Kinlough-Rathbone RL; Mustard JF
    J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation.
    Fouque F; Vargaftig BB
    Br J Pharmacol; 1984 Nov; 83(3):625-33. PubMed ID: 6439269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
    Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G
    Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different effects of thromboxane synthetase inhibitors on platelets from different individuals.
    Lancet; 1982 Nov; 2(8308):1156-7. PubMed ID: 6128469
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacological manipulation of canine cyclooxygenase and thromboxane synthetase in vivo: differential renal and platelet recovery rates.
    Oshima T; McCluskey ER; Honda A; Needleman P
    J Pharmacol Exp Ther; 1984 May; 229(2):598-602. PubMed ID: 6425495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
    Hornberger W; Patscheke H
    Eicosanoids; 1989; 2(4):241-8. PubMed ID: 2517034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.